Curcumin is considered a potential anti-asthmatic agent owing to its anti-inflammatory properties. The objective of the present study was to prepare curcumin-containing poly(lactic-co-glycolic acid)-based microscale discoidal polymeric particles (Cur-PLGA-DPPs) and evaluate their anti-asthmatic properties using a murine asthma model. Cur-PLGA-DPPs were prepared using a top-down fabrication method. The prepared Cur-PLGA-DPPs had a mean particle size of 2.5 ± 0.4 μm and a zeta potential value of −34.6 ± 4.8 mV. Ex vivo biodistribution results showed that the Cur-PLGA-DPPs mainly accumulated in the lungs and liver after intravenous injection. Treatment with Cur-PLGA-DPPs effectively suppressed the infiltration of inflammatory cells in bronchoalveolar lavage fluid, and reduced bronchial wall thickening and goblet-cell hyperplasia compared to those in the phosphate-buffered-saline-treated control group. No significant changes in hematology and blood biochemistry parameters were observed after treatment with Cur-PLGA-DPPs. At equal curcumin concentrations, treatment with Cur-PLGA-DPPs exhibited better therapeutic efficacy than treatment with free curcumin. Our results suggest that the microscale Cur-PLGA-DPPs can be potentially used as a lung-targeted asthma therapy.

中文翻译：

---

姜黄素的微型盘状聚合物颗粒在小鼠哮喘模型中的疗效。

由于姜黄素具有抗炎作用，因此被认为是一种潜在的抗哮喘药。本研究的目的是制备含有聚姜黄素（乳酸-共-乙醇酸）为基础的微米级盘状聚合物颗粒（Cur-PLGA-DPPs），并使用鼠哮喘模型评估其抗哮喘特性。使用自顶向下的制造方法制备Cur-PLGA-DPP。制备的Cur-PLGA-DPP具有2.5±0.4μm的平均粒径和-34.6±4.8mV的ζ电位值。离体生物分布结果表明，Cur-PLGA-DPPs静脉注射后主要聚集在肺和肝中。与磷酸盐缓冲盐水治疗对照组相比，Cur-PLGA-DPPs治疗可有效抑制支气管肺泡灌洗液中炎性细胞的浸润，并减少支气管壁增厚和杯状细胞增生。用Cur-PLGA-DPPs治疗后未观察到血液学和血液生化参数的显着变化。在相同的姜黄素浓度下，用Cur-PLGA-DPPs进行治疗比用游离姜黄素进行治疗具有更好的疗效。我们的结果表明，微型Cur-PLGA-DPPs可以潜在地用作针对肺的哮喘治疗。